Tag Archives: Deal

← Older posts Newer posts →

Boston Tech Watch: .406, Circle, Haven, Shift, LinkSquares & More

The Amazon, Berkshire Hathaway, and JPMorgan-led healthcare moonshot has a name. The venture capital dollars continued to roll in for A.I. startups. The Akamai-Janrain deal was pegged at $125 million. And a local VC firm is reloading for a new fund. Read on for more of this week’s Boston technology and innovation news. —Shift Technology, […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Boston Tech Watch: .406, Circle, Haven, Shift, LinkSquares & More

Angel Networks Most Active Texas Investors Since 2010, Report Says

Austin — Two angel networks in Texas have been the most active investors in the state since 2010. The Houston Angel Network leads the list with 145 investments during the past nine years, followed by the Central Texas Angel Network in Austin with 144 deals, according to data compiled by Seattle-based PitchBook. Capital Factory, which runs […]

Posted in National blog main, Texas, Texas blog main, Texas top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Angel Networks Most Active Texas Investors Since 2010, Report Says

Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M

Argenx, a Dutch firm with a pipeline of investigational antibody-based therapies, will pay San Diego-based Halozyme to use its drug delivery technology to develop subcutaneous versions of some of the drugs Argenx is developing to treat rare autoimmune diseases and cancers. The technology Halozyme (NASDAQ: HALO) is licensing, called Enhanze, allows drugs that would otherwise […]

Posted in Boston blog main, National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M

Tidelift’s “Netflix for Open-Source Software” Model Gets $25M Boost

Tidelift, a startup trying to solve some of the open-source software industry’s problems around compensation and security, said it wrapped up a $25 million investment to gather more publicly maintained software projects under its umbrella. The Boston-based company, founded in 2017 by four Red Hat vets, said it is trying to recreate what Red Hat […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Tidelift’s “Netflix for Open-Source Software” Model Gets $25M Boost

Bio Roundup: Alnylam’s Moment, Read on Rebates, Skinny Plans & More

Millions of people might be on vacation as we hit the dog days, but drug makers and politicians aren’t taking a break from the gamesmanship over high drug prices. After two years of blowing smoke, the Trump administration is threatening action on a few fronts, including against the powerful middlemen known as PBMs that decide […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Alnylam’s Moment, Read on Rebates, Skinny Plans & More

Former Zulily Employees Announce Digital Ad Platform New Engen

A group of Seattle entrepreneurs, who worked at flash sale site Zulily before it sold for $2.4 billion in 2015, are announcing a new company that has been developing a technology to help advertisers figure out where to efficiently buy digital ads. Called New Engen, the company was founded in 2016 by CEO David Atchison […]

Posted in National blog main, Seattle, Seattle blog main, Seattle top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Former Zulily Employees Announce Digital Ad Platform New Engen

Bio Roundup: Trump Health, Cholesterol Wars, 23andMe OK & More

Trump administration health officials were out on the stump this week, talking tough about drug prices and healthcare value, encouraging the private sector to take the lead but letting everyone know the federal government is willing to push. In the debate over high drug prices, arguably no class of drug has been punished more by […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Trump Health, Cholesterol Wars, 23andMe OK & More

Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost

When it comes to spending cash on potential combinations for its cancer immunotherapy drugs, Bristol-Myers Squibb (NYSE: BMY) isn’t afraid of the b-word: billions. The New York-based pharma firm is paying Nektar Therapeutics (NASDAQ: NKTR) of San Francisco $1 billion in cash and buying another $850 million in shares, all to grab partial rights to […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost

After 2nd Bet on Familiar Drug, Impact Bio Lands $1B Celgene Buyout

Celgene (NASDAQ: CELG) has kicked off J.P. Morgan week—the annual healthcare investment gathering in San Francisco—with a blockbuster deal, acquiring privately held Impact Biomedicines for $1.1 billion upfront in cash. More is in the offing if Impact’s drug fedratinib passes a series of regulatory and sales hurdles. The deal rewards the determination of San Diego […]

Posted in National blog main, National top stories, New York blog main, New York top stories, San Diego, San Diego blog main, San Diego top stories | Tagged , , , , , , , , , , , , , , , | Comments Off on After 2nd Bet on Familiar Drug, Impact Bio Lands $1B Celgene Buyout

Bio Roundup: ICER Eyes Cost, Azar at HHS, Gates’s ALZ Cash & More

In our roundup this week, Alzheimer’s disease is in the news, thanks to billionaire Bill Gates and his personal pledge of $100 million toward R&D. That could equal the amount one startup hopes to raise in an IPO to develop drugs for Alzheimer’s and other brain diseases. If a treatment became available, could our health […]

Posted in Boston blog main, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: ICER Eyes Cost, Azar at HHS, Gates’s ALZ Cash & More← Older posts Newer posts →